Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Stayble Therapeutics

0,25 SEK

-12,59 %

Mindre end 1K følgere

STABL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-12,59 %
+3,26 %
-27,47 %
-46,06 %
-50,29 %
-53,91 %
-93,60 %
-96,46 %
-96,61 %

Stayble Therapeutics operates in the pharmaceutical industry. The company specializes in research and development of injection treatments for pain caused by herniated discs. The drug candidates are developed and based on a proprietary technological platform. Most operations are found in the Nordic market and the company has its headquarters in Gothenburg.

Læs mere
Markedsværdi
16,32 mio. SEK
Aktieomsætning
80,14 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
25.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Eksterne analyser29.8.2025, 07.42

Stayble Therapeutics: Rapportkommentar Q2'25 - Kalqyl

Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det andra kvartalet. Nettoomsättningen uppgick till 0,0 MSEK (0,0), medan övriga rörelseintäkter landade på 0,0 MSEK (0,4). EBIT uppgick till -1,9 MSEK (-3,4). ...

Stayble Therapeutics
Pressemeddelelse14.1.2025, 07.00

Stayble Therapeutics: Interview with US payer expert on the US market and STA363's potential

Stayble Therapeutics
Pressemeddelelse2.1.2025, 07.00

Stayble Therapeutics: Interview with Jane Buus Laursen - an experienced pharma dealmaker and Board member of Stayble

Stayble Therapeutics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse11.12.2024, 11.30

Stayble Therapeutics reports additional data strengthening the STA363 treatment for pain caused by disc herniation

Stayble Therapeutics
Selskabsmeddelelse13.11.2024, 18.01

Stayble Therapeutics' STA363 receives positive phase 1b results

Stayble Therapeutics
Pressemeddelelse12.1.2024, 07.15

Stayble Therapeutics: Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"

Stayble Therapeutics
Pressemeddelelse18.12.2023, 07.24

Stayble Therapeutics: BioStock: Stayble's new analyses of phase IIb study strengthen disc herniation project

Stayble Therapeutics
Pressemeddelelse22.11.2023, 07.24

BioStock: Stayble Therapeutics shifts focus to phase Ib study in disc herniation

Stayble Therapeutics
Pressemeddelelse9.11.2023, 13.29

Stayble Therapeutics: BioStock: Stayble did not reach the primary endpoint in phase IIb

Stayble Therapeutics
Pressemeddelelse3.11.2023, 08.56

BioStock: Stayble Therapeutics presents phase IIb data within one month

Stayble Therapeutics
Pressemeddelelse14.9.2023, 06.45

Stayble Therapeutics: BioStock: Stayble reports last patient last visit in the phase IIb study

Stayble Therapeutics
Pressemeddelelse4.9.2023, 08.26

Stayble Therapeutics: BioStock: Stayble enrols the first patient in herniated disc study

Stayble Therapeutics
Pressemeddelelse25.8.2023, 06.52

BioStock: Progress for Stayble Therapeutics in the second quarter

Stayble Therapeutics
Pressemeddelelse24.7.2023, 08.07

Stayble Therapeutics: BioStock: Stayble's phase IIb study nears the finishing line

Stayble Therapeutics
Eksterne analyser13.7.2023, 07.36

Stayble Therapeutics: Resultat från fas 2-studien med STA363 väntas i Q4 - Analysguiden

Bolaget levererar på uppföljningsmålet och Fas 2b-studien med STA363 löper enligt plan. Studieresultat väntas i Q4 och ett motiverat värde vid 5,5 kronor upprepas.

Stayble Therapeutics
Pressemeddelelse20.6.2023, 06.23

BioStock: Stayble Therapeutics looks towards its most important year so far

Stayble Therapeutics
Pressemeddelelse27.4.2023, 08.52

BioStock: Newly appointed CMO sees potential in Stayble Therapeutics

Stayble Therapeutics
Pressemeddelelse18.4.2023, 06.21

Stayble Therapeutics: BioStock: Stayble presents additional positive interim data

Stayble Therapeutics
Pressemeddelelse7.3.2023, 07.51

Stayble Therapeutics: BioStock: Stayble adds disc herniation to the pipeline - study approved

Stayble Therapeutics
Pressemeddelelse15.2.2023, 07.50

Stayble Therapeutics: BioStock: Stayble is done with the 6-month follow-up

Stayble Therapeutics
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.